Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Who can take part

• Confirmed newly diagnosed symptomatic acute venous thromboembolism (VTE) [proximal lower extremity deep vein thrombosis (DVT) or segmental or greater pulmonary embolism (PE)]
• Age ≥ 18 years old
• Informed consent obtained

Who cannot take part

• Have received > 72 hours of therapeutic anticoagulation
• Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to:; active bleeding,; active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally advanced or metastatic disease; or c) currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or d) a hematologic malignancy not in complete remission,; weight > 120 kg,; liver disease (Child-Pugh Class B or C),; use of contraindicated medications; another indication for long-term anticoagulation (e.g. atrial fibrillation); pregnant (note below) or breastfeeding (Note: as reported by the patient or a pregnancy test will be ordered at the discretion of the treating physician for women of childbearing potential as per standard of care)
• Creatinine clearance < 30 ml/min calculated with the Cockcroft-Gault formula